Healthcare Professionals
Astra XT MRI
SureScan Pacemaker
Built for long-lasting performance
Astra™ XT MRI SureScan™ Pacing Systems are built keeping long-lasting performance in mind and come equipped with a new hardware architecture that optimizes circuitry to reduce current drain and improve longevity.1,2
- Dual Chamber — 15.3 years*
- Single Chamber — 17.9 years*
*DR: MVP™, SR: VVI 50%, 500 ohm, 2.5V, pre-storage EGM off
Reduce Unnecessary RV Pacing
With updated MVP algorithm2
Now with the option to control maximum AV interval
- MVP algorithm reduces unnecessary RV pacing by 99%.6
- RV pacing is associated with a 1% increase in risk of AF for each 1% increase in RV pacing.7
- RV Pacing is also associated with an increased risk of HF hospitalisation.7
Reduce The Progression To Permanent AF
With Reactive ATP algorithm
In the MINERVA trial,3 Reactive ATP algorithm demonstrates
- 61% relative reduction for the progression to permanent AF
- 42% relative reduction in AF-related hospitalisations and 68% relative reduction in ER visits4
- 45% relative reduction for AF cardioversions5
Expanded MRI Access
Astra XT MRI SureScan pacing systems are approved for safe use in the MR environment, when MR conditions for use are met. With Astra XT MRI, patients have access to 1.5T and 3T full body scanning.
- Our SureScan devices and leads work in any combination.
- Scanning conditions are simple; no MRI exclusion zone, no patient height restriction, no MRI duration restrictions.
Visit the Product Search page on MRISureScan.com to find more information on how to verify, program and safely scan an pacemaker with MRI SureScan Technology.
MODEL SPECIFICATIONS
Astra MRI SureScan Specifications Sheets
| Device | Model Number | Asset |
|---|---|---|
|
Astra XT SR MRI SureScan |
X2SR01 |
|
|
Astra XT DR MRI SureScan |
X2DR01 |
1
Medtronic, Advisa DR MRI™ SureScan™ A3DR01, clinician manual, M927882A001C, 2009-07-23.
2
Medtronic, Astra™ XT DR MRI SureScan™ X2DR01, Device manual, M964366A001 B, 2016-10-22. Medtronic, Astra™ XT SR MRI SureScan™ X2SR01, Device manual, M964368A001 B, 2016-10-20.
3
Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicenter international trial. G. Boriani et al. European Heart Journal (2014) 35, 2352–2362
4
G. Boriani et al. Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm. 2015 Jun;12(6):1192-200
5
Minerva trial. Supplementary material online, Appendix. http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu165/-/DC1
6
Gillis AM, et al. Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block. PACE 2006; 29:697–705
7
Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. June 17, 2003;107(23):2932-2937.